首页> 外文期刊>New Microbes and New Infections >First report of colistin resistance among carbapenem-resistant Acinetobacter baumannii isolates recovered from hospitalized patients in Egypt
【24h】

First report of colistin resistance among carbapenem-resistant Acinetobacter baumannii isolates recovered from hospitalized patients in Egypt

机译:从埃及住院患者中回收的对碳青霉烯类耐药鲍曼不动杆菌中大肠菌素耐药性的首次报道

获取原文
获取外文期刊封面目录资料

摘要

Acinetobacter baumannii is an opportunistic pathogen that poses an increasing threat in the health-care community. Colistin is one of the promising options for treatment of multidrug-resistant A.?baumannii . The current study investigated the emergence of colistin resistance among carbapenem-resistant strains of A.?baumannii in Egypt. It involved identification of clinically recovered A . baumannii isolates using the VITEK-2 system, and screening of their antimicrobial susceptibilities using broth microdilution techniques. Characterizations of carbapenemase and 16S rRNA methyltransferase genes were performed using PCR. Colistin-resistance determinants were characterized by sequencing. Carbapenem-resistant A.?baumannii isolates ( n =?40) showed resistance to amoxicillin-clavulanic acid, cefotaxime, gentamicin and amikacin. Most isolates revealed resistance to ciprofloxacin (95%; n =?38) and co-trimoxazole (92.5%; n =?37). Resistance to tobramycin and doxycycline was 80% ( n =?32) and 62.5% ( n =?25), respectively. Only two A.?baumannii isolates demonstrated colistin resistance. Carbapenemase activity was tested by modified Hodge test and 78% of isolates were positive. All isolates carried bla OXA-51-like genes whereas bla -OXA-23 was detected in 80% ( n =?32) of isolates. Among 16S rRNA methylase genes, armA was detected in 22.5% ( n =?9) of the isolates. Analyses of lpxA , lpxC , lpxD and pmrCAB genetic sequences suggest that colistin resistance could be attributed to mutations in pmrCAB genes. Alarmingly, colistin resistance was associated with high levels of resistance to other antimicrobials. The current findings represent a serious health-care problem capable of restraining future therapeutic options.
机译:鲍曼不动杆菌是一种机会病原体,对医疗保健界构成越来越大的威胁。 Colistin是治疗多重耐药鲍氏不动杆菌的有前途的选择之一。目前的研究调查了埃及对碳青霉烯类耐药的鲍曼不动杆菌菌株中大肠菌素抗性的出现。它涉及鉴定临床上恢复的A。使用VITEK-2系统分离鲍曼氏菌,并使用肉汤微稀释技术筛选其抗菌药敏性。碳青霉烯酶和16S rRNA甲基转移酶基因的表征使用PCR进行。共利斯汀抗性决定簇通过测序来表征。耐碳青霉烯的鲍曼不动杆菌分离株(n = 40)对阿莫西林-克拉维酸,头孢噻肟,庆大霉素和丁胺卡那霉素具有抗性。大多数分离株显示对环丙沙星(95%; n =?38)和复方新诺美唑(92.5%; n =?37)有抗性。对妥布霉素和强力霉素的耐药性分别为80%(n = 32)和62.5%(n = 25)。仅两个鲍曼不动杆菌分离株表现出大肠菌素抗性。碳青霉烯酶活性通过改良的Hodge测试进行了测试,其中78%的分离物呈阳性。所有分离株均带有bla OXA-51 样基因,而在80%(n =?32)分离株中检测到bla- OXA-23 。在16S rRNA甲基化酶基因中,在22.5%(n =?9)的分离物中检测到armA。对lpxA,lpxC,lpxD和pmrCAB遗传序列的分析表明,大肠菌素抗性可能归因于pmrCAB基因的突变。令人震惊的是,大肠菌素抗性与对其他抗菌剂的高水平抗性相关。当前的发现代表了严重的医疗保健问题,能够限制未来的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号